总体生存率-话题@MedSci

#总体生存率#

10篇内容 | 1328人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2278764, encodeId=8af322e8764ab, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=adf23354483' target=_blank style='color:#2F92EE;'>#化疗#</a> <a href='/topic/show?id=1a5a58e00ad' target=_blank style='color:#2F92EE;'>#新辅助治疗#</a> <a href='/topic/show?id=a07f82814ec' target=_blank style='color:#2F92EE;'>#肿瘤免疫治疗#</a> <a href='/topic/show?id=35a050454a5' target=_blank style='color:#2F92EE;'>#循环肿瘤DNA#</a> <a href='/topic/show?id=2df452e4557' target=_blank style='color:#2F92EE;'>#总体生存率#</a> <a href='/topic/show?id=fc2be734870' target=_blank style='color:#2F92EE;'>#纳武利尤单抗#</a>, objectTitle=新突破！新辅助纳武利尤单抗联合化疗显著提升可切除非小细胞肺癌5年生存率, objectType=article, longId=893669, objectId=d020893669b8, topicUrl=null, isHasObj=0, objectCover=, objectUrl=/article/show_article.do?id=d020893669b8, replyNumber=0, likeNumber=11, createdTime=2025-08-26, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=威斯康星, moduleDTOList=[ModuleDTO(moduleId=d020893669b8, moduleTitle=新突破！新辅助纳武利尤单抗联合化疗显著提升可切除非小细胞肺癌5年生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d020893669b8)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1668533, encodeId=4a991668533c5, content=<a href='/topic/show?id=2df452e4557' target=_blank style='color:#2F92EE;'>#总体生存率#</a>, objectTitle=NEJM：瑞博西尼加来曲唑治疗晚期乳腺癌的总体生存率, objectType=article, longId=300433, objectId=bab930043353, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bab930043353, replyNumber=0, likeNumber=106, createdTime=2022-12-04, rootId=0, userName=般若傻瓜, userId=bf0826335696, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bab930043353, moduleTitle=NEJM：瑞博西尼加来曲唑治疗晚期乳腺癌的总体生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bab930043353)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1668532, encodeId=ff74166853285, content=<a href='/topic/show?id=2df452e4557' target=_blank style='color:#2F92EE;'>#总体生存率#</a>, objectTitle=Imfinzi联合tremelimumab治疗肝癌，III期试验显示可提高总体生存率, objectType=article, longId=218686, objectId=4c14218686ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4c14218686ce, replyNumber=0, likeNumber=86, createdTime=2021-11-13, rootId=0, userName=般若傻瓜, userId=bf0826335696, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4c14218686ce, moduleTitle=Imfinzi联合tremelimumab治疗肝癌，III期试验显示可提高总体生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4c14218686ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1668530, encodeId=1b88166853066, content=<a href='/topic/show?id=2df452e4557' target=_blank style='color:#2F92EE;'>#总体生存率#</a>, objectTitle=Eur Heart J：预防性ACEi治疗与杜氏肌营养不良症患者总体生存率之间的关联, objectType=article, longId=208918, objectId=f491208918f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f491208918f8, replyNumber=0, likeNumber=102, createdTime=2021-11-05, rootId=0, userName=般若傻瓜, userId=bf0826335696, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f491208918f8, moduleTitle=Eur Heart J：预防性ACEi治疗与杜氏肌营养不良症患者总体生存率之间的关联, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f491208918f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1668529, encodeId=9d4f16685294c, content=<a href='/topic/show?id=2df452e4557' target=_blank style='color:#2F92EE;'>#总体生存率#</a>, objectTitle=阿斯利康的Imfinzi无法提高头颈癌患者的总体生存率, objectType=article, longId=207015, objectId=bc7b20e0156f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc7b20e0156f, replyNumber=0, likeNumber=78, createdTime=2021-11-08, rootId=0, userName=般若傻瓜, userId=bf0826335696, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc7b20e0156f, moduleTitle=阿斯利康的Imfinzi无法提高头颈癌患者的总体生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc7b20e0156f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1668531, encodeId=3cfb16685313f, content=<a href='/topic/show?id=2df452e4557' target=_blank style='color:#2F92EE;'>#总体生存率#</a>, objectTitle=DCR: 围手术期输血不能改变直肠癌根治性切除术后的总体生存率, objectType=article, longId=216329, objectId=f50121632919, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f50121632919, replyNumber=0, likeNumber=96, createdTime=2021-12-13, rootId=0, userName=般若傻瓜, userId=bf0826335696, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f50121632919, moduleTitle=DCR: 围手术期输血不能改变直肠癌根治性切除术后的总体生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f50121632919)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1668528, encodeId=806e166852825, content=<a href='/topic/show?id=2df452e4557' target=_blank style='color:#2F92EE;'>#总体生存率#</a>, objectTitle=ASCO 2020：信达生物的抗PD-L1单抗TYVYT（Sintilimab）显着改善了食管鳞状细胞癌患者的总体生存率(ORIENT-2研究), objectType=article, longId=194241, objectId=a91619424150, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a91619424150, replyNumber=0, likeNumber=93, createdTime=2020-08-05, rootId=0, userName=般若傻瓜, userId=bf0826335696, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a91619424150, moduleTitle=ASCO 2020：信达生物的抗PD-L1单抗TYVYT（Sintilimab）显着改善了食管鳞状细胞癌患者的总体生存率(ORIENT-2研究), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a91619424150)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1668527, encodeId=7234166852e8b, content=<a href='/topic/show?id=2df452e4557' target=_blank style='color:#2F92EE;'>#总体生存率#</a>, objectTitle=默沙东的Keytruda治疗小细胞肺癌的III期临床，未能明显改善患者的总体生存率, objectType=article, longId=185921, objectId=fcce18592178, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcce18592178, replyNumber=0, likeNumber=85, createdTime=2020-02-01, rootId=0, userName=般若傻瓜, userId=bf0826335696, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcce18592178, moduleTitle=默沙东的Keytruda治疗小细胞肺癌的III期临床，未能明显改善患者的总体生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fcce18592178)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1668526, encodeId=0d8d16685261e, content=<a href='/topic/show?id=2df452e4557' target=_blank style='color:#2F92EE;'>#总体生存率#</a>, objectTitle=CCLM：结直肠腺癌中microRNA-28-5p高表达可预测淋巴结阴性患者的短期复发和非转移性疾病患者较低的总体生存率, objectType=article, longId=145555, objectId=1638145555dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1638145555dc, replyNumber=0, likeNumber=77, createdTime=2018-08-03, rootId=0, userName=般若傻瓜, userId=bf0826335696, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1638145555dc, moduleTitle=CCLM：结直肠腺癌中microRNA-28-5p高表达可预测淋巴结阴性患者的短期复发和非转移性疾病患者较低的总体生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1638145555dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1668525, encodeId=d2c3166852574, content=<a href='/topic/show?id=2df452e4557' target=_blank style='color:#2F92EE;'>#总体生存率#</a>, objectTitle=Liver Int：与病毒性HCC患者相比，隐型肝癌患者的肿瘤更大，肿瘤分期愈晚，总体生存率较低, objectType=article, longId=138154, objectId=208313815466, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=208313815466, replyNumber=0, likeNumber=84, createdTime=2018-09-12, rootId=0, userName=般若傻瓜, userId=bf0826335696, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=208313815466, moduleTitle=Liver Int：与病毒性HCC患者相比，隐型肝癌患者的肿瘤更大，肿瘤分期愈晚，总体生存率较低, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=208313815466)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1668524, encodeId=846b16685244c, content=<a href='/topic/show?id=2df452e4557' target=_blank style='color:#2F92EE;'>#总体生存率#</a>, objectTitle=SCI REP：卡培他滨和紫杉醇治疗转移性胰腺癌患者总体生存率的生化和遗传预测因子！, objectType=article, longId=105032, objectId=80fb105032bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=80fb105032bc, replyNumber=0, likeNumber=84, createdTime=2017-10-15, rootId=0, userName=般若傻瓜, userId=bf0826335696, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=80fb105032bc, moduleTitle=SCI REP：卡培他滨和紫杉醇治疗转移性胰腺癌患者总体生存率的生化和遗传预测因子！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=80fb105032bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

总体生存率

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#非小细胞肺癌# #化疗# #新辅助治疗# #肿瘤免疫治疗# #循环肿瘤DNA# #总体生存率# #纳武利尤单抗#

新突破！新辅助纳武利尤单抗联合化疗显著提升可切除非小细胞肺癌5年生存率

2025-08-26发表于威斯康星

般若傻瓜 (审核中...)

前往app查看评论内容

#总体生存率#

NEJM：瑞博西尼加来曲唑治疗晚期乳腺癌的总体生存率

2022-12-04

般若傻瓜 (审核中...)

前往app查看评论内容

#总体生存率#

Imfinzi联合tremelimumab治疗肝癌，III期试验显示可提高总体生存率

2021-11-13

般若傻瓜 (审核中...)

前往app查看评论内容

#总体生存率#

Eur Heart J：预防性ACEi治疗与杜氏肌营养不良症患者总体生存率之间的关联

2021-11-05

般若傻瓜 (审核中...)

前往app查看评论内容

#总体生存率#

阿斯利康的Imfinzi无法提高头颈癌患者的总体生存率

2021-11-08

般若傻瓜 (审核中...)

前往app查看评论内容

#总体生存率#

DCR: 围手术期输血不能改变直肠癌根治性切除术后的总体生存率

2021-12-13

般若傻瓜 (审核中...)

前往app查看评论内容

#总体生存率#

ASCO 2020：信达生物的抗PD-L1单抗TYVYT（Sintilimab）显着改善了食管鳞状细胞癌患者的总体生存率(ORIENT-2研究)

2020-08-05

般若傻瓜 (审核中...)

前往app查看评论内容

#总体生存率#

默沙东的Keytruda治疗小细胞肺癌的III期临床，未能明显改善患者的总体生存率

2020-02-01

般若傻瓜 (审核中...)

前往app查看评论内容

#总体生存率#

CCLM：结直肠腺癌中microRNA-28-5p高表达可预测淋巴结阴性患者的短期复发和非转移性疾病患者较低的总体生存率

2018-08-03

般若傻瓜 (审核中...)

前往app查看评论内容

#总体生存率#

Liver Int：与病毒性HCC患者相比，隐型肝癌患者的肿瘤更大，肿瘤分期愈晚，总体生存率较低

2018-09-12

般若傻瓜 (审核中...)

前往app查看评论内容

#总体生存率#

SCI REP：卡培他滨和紫杉醇治疗转移性胰腺癌患者总体生存率的生化和遗传预测因子！

2017-10-15

科室
- - 订阅+
  - 更多科室
工具
服务